University of Alabama in Huntsville

LOUIS
Doctor of Nursing Practice (DNP)

UAH Electronic Theses and Dissertations

2017

Scholarly quality improvement project to reduce hospitalization
rates due to pneumonia in the nursing home population
Bertha Carrion

Follow this and additional works at: https://louis.uah.edu/uah-dnp

Recommended Citation
Carrion, Bertha, "Scholarly quality improvement project to reduce hospitalization rates due to pneumonia
in the nursing home population" (2017). Doctor of Nursing Practice (DNP). 12.
https://louis.uah.edu/uah-dnp/12

This Doctor of Nursing Practice (DNP) is brought to you for free and open access by the UAH Electronic Theses and
Dissertations at LOUIS. It has been accepted for inclusion in Doctor of Nursing Practice (DNP) by an authorized
administrator of LOUIS.

SCHOLARLY QUALITY IMPROVEMENT PROJECT TO REDUCE HOSPITALIZATION
Scholarly Quality Improvement Project to Reduce Hospitalization Rates
Due to Pneumonia in the Nursing Home Population
PROBLEM
More than 33% of long-term Medicare and Medicaid eligible beneficiaries who were
residents of nursing homes were hospitalized which amounted to almost one million
hospitalizations (Walsh, Freiman, Haber, Bragg, Ouslander, & Weiner, 2010). Of these, 39%
could have been prevented (Walsh et al., 2010). According to Walsh et al. (2010), 78% of the
possibly avoidable hospitalizations were due to the following five conditions: pneumonia,
congestive heart failure (CHF), urinary tract infections (UTI), dehydration, and chronic
obstructive pulmonary disease (COPD). Pneumonia was responsible for approximately 30% of
the potentially preventable hospitalizations (Walsh et al). Other conditions that may lead to
avoidable hospitalization are anemia, constipation, diarrhea, gastroenteritis, C. Difficile, falls,
and others (Segal, Rollins, Hodges, & Roozeboom, 2014).
About 25% of nursing home residents were hospitalized in 2011 costing Medicare alone
$14.3 billion (Department of Health and Human Services, 2011). Pneumonia was the second
highest cause of hospitalization in 2011 (DHHS, 2011). These possibly avoidable
hospitalizations cost Medicare $3 billion and Medicaid $463 million annually (Walsh et al,
2010). Each hospitalization cost $7,846 to Medicare and $321 to Medicaid (Walsh et al., 2010).
Hospitalization due to pneumonia costs approximately $9,300 per admission (Pfuntner, Wier, &
Steiner, 2013). Appropriate monitoring and treatment of diverse chronic and acute conditions
within the nursing home population such as having on-site clinicians, conducting necessary
laboratory tests, providing intravenous fluids, and practicing quality care in assessing acute
episodes can reduce hospitalizations (Ouslander, Lamb, Perloe, Givens, Kluge, Rutland, Atherly,
5
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& Saliba, 2010). Close to 50% of hospital admissions within the nursing home population
occurred in the final year of life costing $1 billion to Medicare (Xing, Dana, Mukamel, &
Temkin-Greener, 2013). As baby boomers age leading to an increase in the geriatric population,
financial resources for Medicare and Medicaid programs must be better managed.
PICOT
In seniors living in nursing homes, will implementing a clinical protocol that focuses on
primary, secondary and tertiary prevention, reduce the pneumonia hospitalization rates in nursing
home residents participating in this study as compared to residents of the same nursing homes
not participating in a two-month period? The purpose of the scholarly practice project is to
reduce hospitalization of seniors in nursing homes due to pneumonia. The population will
include Medicare and Medicaid senior nursing home resident members who are having health
care managed by five different nurse practitioners in Miami-Dade County, Florida and have a
new suspected diagnosis or condition of pneumonia. It will also include residents who have not
received either the pneumococcal vaccine or the influenza vaccine. The protocol being
implemented includes primary prevention, secondary prevention, tertiary prevention, assessment,
plan of care, intervention, and evaluation of care provided to patients in nursing homes who are
at risk of pneumonia incidence, morbidity, and mortality. The duration of the data collection will
be a period of three months.
REVIEW OF EVIDENCE
A search conducted in CINAHL and Cochrane database using nursing homes and
hospital admission published between 2001-2015 yielded 278 results. Potential reasons for
unplanned hospitalizations of nursing home (NH) residents include Beers inappropriate
medications (Price, Sylvie, Holman, Sanfilippo, & Emery, 2014); processes (Crilly, Chaboyer, &
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Wallis, 2011); coordination, (Kirsebom, Wadenstein, & Hedstrom, 2012); pressure ulcers
(Keelaghan, Margolis, Zhan & Baumgarten, 2008; Lynn, J., West, J., Hausmann, S., Gifford, D.,
Nelson, R., McGann, P., & Ryan, J., 2007); advanced care planning (Baron, Kirsten, Walsh, et
al., 2015); assessment of functional decline due to pressure ulcers, urinary incontinence,
malnutrition, pain, falls, and cognitive impairment (Lee & Rantz, 2008); methicillin-resistant
Staphylococcus aureus (MRSA) (Torres & Sampathkumar, 2013); dehydration/hypernatraemia
(Wolff, Stuckler & McKee, 2015); influenza (Gorišek Miksić, Uršič, Simonović, Lusa, Lobnik
Rojko, Petrovec, & Strle, 2015); CHF (Gruneir, Bell, Bronskill, Schull, Anderson, & Rochon,
2010); and infections (Koch, Eriksen, Elstrøm, Aavitsland, Harthug, 2009).
A search in CINAHL utilizing nursing homes and avoidable hospitalizations yielded 16
results. When limiting this search to only those readily available in full text format, there were
nine articles. Of these nine, four had information relevant to the project. Xing, Mukamel, and
Temkin-Greener (2013) revealed that in 2007, there were 143,058 potentially avoidable
hospitalizations each costing on average $6,793. Xing, Mukamel, and Temkin-Greener
identified the potentially avoidable hospitalizations (PAHs) by condition as the following in
order of most prevalence: pneumonia, CHF, UTI, dehydration, falls/trauma, COPD, and others.
Not all the PAHs may be avoidable due to other factors such as decisions of hospital emergency
department clinicians, patient preferences, family preferences, no advance care plan directives on
file, unidentified hospice candidates, legal liability concerns, available diagnostic services, and
available pharmacy services, (Maslow & Ouslander, 2012).
Xing (2013) suggested that PAHs due to CHF, UTI, and dehydration account for almost
40% of the PAHs and should be avoided. Hospitalization due to pneumonia may be a little more
difficult to avoid due to the clinical complexity in end-of-life patients (Xing, 2013). The quality
7
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improvement program suggested in this project directs great effort and care in reducing
hospitalization due to pneumonia. However, hospitalization due to pneumonia may be necessary
if after every effort has been made, the patient has severe respiratory distress. Xing (2013)
mentions that there some studies have concluded that there is no significant mortality difference
between NH residents treated on site and those treated at the hospital. Kuo, Raji & Goodwin
(2013) conclude the primary care providers (PCPs) that devote greater percentage of time and
clinical effort had less PAHs than PCPs who provide less time and clinical effort. Analysis of
this research reveals that PAHs due to pneumonia can be reduced by implementing quality
improvement programs or clinical guideline protocols.
Quality improvement programs and methods have been used to reduce re-hospitalization.
The Interventions to Reduce Acute Care Transfers (INTERACT) quality improvement project
has three main strategies as follow: identify, assess, and manage conditions proactively; manage
selected conditions in the nursing home; and improve advanced care planning (palliative care)
(Ouslander, Lamb, Tappen, Herndon, Diaz, Roos, & Bonner, 2011). INTERACT has many care
path tools that are helpful in guiding clinicians’ decision making processes. The INTERACT
model’s concept of quality improvement involves obtaining institutional support, approval from
stakeholders, teamwork, team rules, aims/scope, and financial considerations (Williams, et al,
2008). INTERACT also states that SMART Goals are specific, measurable, achievable, realistic,
and time defined. The INTERACT project uses a sign called the Stop and Watch Early Warning
Tool which is a great way to help predict worsening health condition that may require special
attention from nurses
NURSING CONCEPT AND THEORETICAL FRAMEWORK
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Betty Neuman’s Systems Model (BNSM; Neuman & Fawcett, 2011) provides a model
framework that informed this project. BNSM views the patient under care as a dynamically
organized system surviving through lines of resistance, normal lines of defense and flexible lines
of defense (Neuman & Fawcett, 2011). When these defenses are strengthened, health (balance,
wellness, harmony, and stability) is achieved. When these defenses are weakened, the core
(patient) is vulnerable and at risk of mortality (Neuman & Fawcett, 2011). The patient is also in
a dynamic equilibrium state with the environment having intrapersonal (infection, behavior),
interpersonal (other people), and extrapersonal stress factors (finances, resources) called by
Neuman as stressors (Neuman & Fawcett, 2011).
In BNSM, primary, secondary, and tertiary prevention care by nurses and others aim to
strengthen the patient’s defense or decrease the stressors as guided by the assessment and plan of
care. The assessment considers both the nurse and patient perspectives (Neuman & Fawcett,
2011). The plan of care includes goals that are short and long term in nature based on the patient
diagnoses and collaborative practice decisions (Neuman & Fawcett, 2011). To ascertain the
success of the interventions, the nurse evaluates how the patient’s defense is responding
(Neuman & Fawcett, 2011). Assessing, diagnosing, planning, intervening and evaluating
describes what the nurse should be continually doing in providing optimum care to the patients.
In this project, the specific protocol established is an attempt to predict potential stressors
of the patients with pneumonia as well as what the process will be for assessment, diagnosing,
planning, implementation, and evaluation, the basic nursing process. It is expected that by using
this protocol, the patient’s health will be strengthened to such a degree that hospitalization is not
needed or needed to a much lesser degree.
PROJECT OVERVIEW
9
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The entire project overview stating protocol in written format may be found in Appendix
A. This protocol includes primary prevention, secondary prevention, and tertiary prevention.
Due to time constraints and practical concerns, the aspects that are not implemented are those
associated with primary prevention.
PRIMARY PREVENTION
To prevent pneumonia, the following have been recommended, pneumococcal
vaccination, influenza vaccination, respiratory hygiene measures, and tobacco cessation
treatments. The focus of primary prevention in the NH will be on pneumococcal vaccination and
influenza vaccination. Respiratory hygiene measures and tobacco cessation though very
important will not be a part of this project.
The facility nurse practitioner (NP) should follow protocol for primary prevention as
found on page one of Appendix A. The NP should collect and record patient’s pneumococcal
vaccination history (Appendix B) using facility records and/or family/health representative
reports and act as the guideline concerning pneumococcal vaccination (Appendix C) suggests.
The NH staff and/or the NP should explain the vaccine to appropriate person(s) using the
pneumococcal vaccine (PCV13 and for PPSV23) vaccine information statements which will be
given. The patient and/or patient representative should receive facility written consent for
authorization for vaccination.
In addition to collecting patient’s pneumococcal vaccination history, the NP should
record the patient’s influenza vaccine history as set forth in Appendix D. The NP should follow
the stated influenza vaccine protocol as seen in page one of Appendix A and as in Appendix E.
The nursing home staff and/or the nurse practitioner should explain the influenza vaccine to
appropriate person(s) using the influenza vaccine information statements which will be given.
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Informed consents should be obtained as appropriate to practice setting and guidelines for the
administration of both the pneumococcal and influenza vaccines.
SECONDARY PREVENTION PROJECT DESIGN
When a patient is suspected to be experiencing an acute episode of pneumonia, proper
care and monitoring must be in place to prevent hospitalization, complications and greater
morbidity, and mortality. The author will provide the skilled nursing facility staff with in-service
education on how to recognize early symptoms of suspected pneumonia using Appendix F. By
using Nursing Home Staff and Multidisciplinary Team Surveillance of Pneumonia (Appendix F)
as a guide, all nursing home staff will be able to recognize and detect possible pneumonia
incidence on patients under long term care. Upon nursing home staff seeing signs and symptoms
of possible pneumonia, they must notify the NP immediately. Nurse practitioners (NPs) will use
Appendix F as a guide as they do rounds in the skilled nursing facility.
Once there is a suspicion that a patient is having an incidence of pneumonia, the NP
should immediately assess the patient and provide appropriate diagnosis and plan of care. NP
should record findings on Appendix G noting the Pneumonia Nursing Home Severity Index as
well as the results from diagnostic testing. Upon assessment of patient, the NP should initiate a
plan of care appropriate to the findings as described in Appendix H. The NP will use page four
of Appendix A as a guide for pneumonia pathogen directed treatment.
TERTIARY PREVENTION OF PNEUMONIA INCIDENCE PROJECT DESIGN
Upon treatment starting for suspected pneumonia, the NP must continue monitoring and
evaluating the patient’s condition to prevent further complications. The Tertiary Prevention of
Pneumonia Incidence protocol (Appendix I) provides a guide to tertiary prevention of
pneumonia. During this time, a list of differential diagnoses should be developed and evaluated.
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In this project, only two differential diagnoses are be monitored and treated which are COPD
(Appendix J) and CHF (Appendix L) exacerbations. The facility NPs will record assessment and
plan of care in Appendix K for COPD and Appendix M for CHF. Many of the patients under
long term care are unable to complete a pulmonary function test and spirometry due to advanced
age, dementia, stroke and other severe comorbidities.
IMPLEMENTATION
To reduce pneumonia hospitalizations in the nursing home setting, it is essential to obtain
stakeholder participation in the project. Walsh, Frieman, Haber, Bragg, Ouslander & Wiener
(2010) demonstrated how almost 30% of the potentially avoidable hospitalizations were due to
pneumonia. Managed care insurance companies, the nursing administrators, collaborative
physicians, NPs, nursing home nurses, nursing home certified nursing assistants, and nursing
home dietician(s) can collaborate to further inform specifically the nursing discipline and in
general all disciplines involved in providing optimum healthcare to nursing home residents.
The five nurse practitioners that participated in this project are as follow: Bertha Carrion,
Sandra Toral, Margarita Cunningham, Laura Costero, and Marta Costas. In March of 2017,
consents from the five nursing homes participating in the project were obtained: (1) Fair Havens
Center, (2) Hampton Court Skilled Nursing and Rehabilitation Center, (3) Harmony Health
Center, (4) Sinai Plaza Rehabilitation and Nursing Center, and (5) South Dade Nursing and
Rehabilitation Center. A total of 275 patients received care from the nurse practitioners and
facilities participating in the project. See Table 1 for details.
Table 1– Number and Ratio of Patient Pool
from Which Patients Diagnosed and Treated Came From
ARNP
Facility
# of Patient Population in Project
ARNP01
South Dade
73
ARNP02
Harmony
79

%
26%
29%
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ARNP03
ARNP04
ARNP05

Sinai Plaza
Fair Havens
Hampton
TOTAL

29
66
28
275

11%
24%
10%
100%

On April 12, 2017, this quality improvement project was approved by the Institutional
Review Board of Human Subjects Committee. All personal information was kept confidential by
implementing the following procedures. All printed files containing any confidential
information were stored in a locked file cabinet in author’s office. No personal information was
made public knowledge as the study participants’ personally identifiable information was not
made known. All online documentation was securely stored and transmitted using secured
virtual private network (VPN), web based platform requiring username and password to obtain
access, secure online fax and Microsoft Windows security measures to login to the laptop. Study
participants were identified by using identification numbers that do not publicly reveal any of the
study participants’ private information such as name, address, social security number,
Medicare/Medicaid identification numbers, insurance member identification numbers, or other
personal private information.
The specific protocol was developed to provide care to patients with susceptibility,
incidence or condition of pneumonia. From 5/1/2017 to 5/7/2017, training was provided to the
five NPs by the author of this project using appendices A-M. Appendix O contains an outline of
the training that was provided to the nursing home staff by the author and facility NP the week of
May 1 through May 7, 2017. The author trained the NPs in group and one-on-one sessions as
outlined in Appendix P. In addition, throughout the entire implementation of this study, the
author was available by phone to address any concerns the NPs may have from Monday through
Friday between 8:00 a.m. to 5:00 p.m. In addition, the author met one-on-one with each NP on a
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weekly basis to go over the study in NP’s own setting. The author and NPs communicated the
plan of care with all parties (nursing home administrators and medical doctors) as well during
this time.
In primary prevention, the goal was to have 30 total participants in pneumococcal
vaccination and/or influenza vaccination throughout the 2-month period of actual provision of
care. Due to time constraints and preference to provide vaccines during flu season, the primary
prevention portion of the protocol was not implemented.
RESULTS OF PROJECT
A total of 275 patients received care from the NPs and facilities participating in the
project. Of these 275 patients, only 18 patients were diagnosed with pneumonia solely or
pneumonia primarily with differential diagnoses of CHF and/or COPD during the project. Table
2 provides a detailed list of the cases that were included in this project.
Table 2 - Detailed List of Cases Diagnosed and Treated in This Project
by Facility and ARNP Including Hospitalization and Mortality
Diagnosis & Treatment
Results
Patient
ID

Facility

ARNP

Pneumonia

CHF

01

Harmony

ARNP02

X

X

02

Harmony

ARNP02

X

X

03

ARNP05

X

X

04

Hampton
South
Dade

ARNP01

X

05

Sinai Plaza

ARNP03

X

06

ARNP02

X

X

X

07

Harmony
Fair
Havens

ARNP04

X

X

X

08

Hampton

ARNP05

X

X

X

COPD Hospitalized

Died

X
X

X
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09

Hampton

ARNP05

X

10

Harmony

ARNP02

X

X

11

ARNP05

X

X

ARNP04

X

ARNP04

X

ARNP01

X

X

15

Hampton
Fair
Havens
Fair
Havens
South
Dade
South
Dade

ARNP01

X

X

16

Harmony

ARNP02

X

X

17

Harmony
South
Dade

ARNP02

X

ARNP01

X

12
13
14

18

X

X

X

X

X

Table 3 shows the number and ratio of cases diagnosed and treated during this project.
Table 3 – Number and Ratio of Cases Diagnosed and Treated
Diagnosis and Treatment
# of
% of
Hospitalized Died
Cases
Cases
Pneumonia Solely
4
22.22%
0%
0%
Pneumonia and CHF
3
16.67%
0%
0%
Pneumonia and COPD
6
38.89%
0%
0%
Pneumonia, CHF, and COPD
5
27.78%
11.11%
5.56%
TOTAL
18
100%
11.11%
5.56%
Using the secondary and tertiary protocols for pneumonia, CHF, and COPD in this project, only
those nursing home residents that experienced pneumonia, CHF, and COPD simultaneously were
hospitalized. Patients numbers 6 and 12 were hospitalized (Table 2). Patient number 6 died.
And patients number 7, 8, and 17 were diagnosed and treated for pneumonia, CHF, and COPD
but did not go to the hospital.
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Table 4 shows the number of incidents on a weekly basis from the weeks ending on
4/23/2017 through 6/25/2017: pneumonia (all cases); pneumonia alone, pneumonia and CHF;
pneumonia and COPD; and pneumonia, CHF, and COPD.

CASES

Table 4 - Weekly Incidents of
Pneumonia; Pneumonia and CHF; Pneumonia and COPD;
and Pneumonia, CHF and COPD
WEEK ENDING
4/23 4/30 5/7 5/14 5/21 5/28 6/4 6/11

6/18

6/25

All Pneumonia

2

0

0

5

1

1

3

0

3

3

Pneumonia Alone

1

0

0

2

0

0

0

0

1

0

Pneumonia and CHF

1

0

0

1

1

0

0

0

0

0

Pneumonia and COPD
Pneumonia, CHF, and
COPD

0

0

0

2

0

0

1

0

1

2

0

0

0

0

0

1

2

0

1

1

EVALUATION OF PROJECT
Table 5 demonstrates the prevalence rate as a percentage of 275 nursing home residents
that had an incidence of pneumonia (all cases) on a weekly basis from the weeks ending in
4/23/2017 through 6/25/2017: pneumonia and CHF; pneumonia and COPD; and pneumonia,
CHF, and COPD.
Table 5 - Weekly Prevalence of Pneumonia; Pneumonia and CHF; Pneumonia and COPD;
And Pneumonia, CHF and COPD
233071421284-Jun 111825-Jun
CASES
Apr
Apr
May
May
May
May
Jun
Jun
0.73%
0
0
1.82% 0.36% 0.36% 1.09%
0 1.09% 1.09%
All
Pneumonia
Pneumonia 0.36%
0
0
0.73%
0
0
0
0 0.36%
0
Alone
Pneumonia 0.36%
0
0
0.36% 0.36%
0
0
0
0
0
and CHF
Pneumonia
0
0
0
0.73%
0
0
0.36%
0 0.36% 0.73%
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and COPD
Pneumonia,
CHF, and
COPD

0

0

0

0

0

0.36%

0.73%

0

0.36%

0.36%

TABLE 6 – Prevalence Rate through 10 Weeks
All Pneumonia
6.55%

Pneumonia
Alone
1.45%

Pneumonia and
CHF
1.09%

Pneumonia and
COPD
2.18%

Pneumonia,
CHF, and COPD
1.82%

Table 6 shows the prevalence rate for the entire 10 weeks of this project. 6.55% of 275
of nursing home residents participating in this project had an incidence of pneumonia with or
without CHF and/or COPD. 1.45% of the NH residents were diagnosed and treated for
pneumonia alone. 1.09% of the residents were diagnosed and treated primarily for pneumonia
and CHF as a differential diagnosis. 2.18% were treated primarily for pneumonia and COPD
secondarily and 1.82% were treated for pneumonia primarily, CHF secondarily, and COPD
secondarily. There were other patients being provided care for CHF and/or COPD but did not
have pneumonia. Those were not included in this project as this project is primarily diagnosing
and treating NH residents who were having an incidence of pneumonia.
Table 7 -All Pneumonia Hospitalization Rate Through 3 Months Beginning 4/15/2017
All Pneumonia

Pneumonia Alone

Pneumonia and
COPD

Pneumonia, CHF,
and COPD

0.73%

0

0

0.73%

The primary prevention aspects of this project were not implementable due to time constraints
and preference to provide vaccines during the flu season. However, nursing home staff as well
as the NPs were trained as to importance of primary prevention in the nursing home population.
17
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The secondary and tertiary prevention of this protocol resulted in 0% hospitalizations in a 3month period beginning 4/15/2017 for those cases that were (1) pneumonia alone, (2) pneumonia
and CHF, and (3) pneumonia, CHF and COPD (See Table 7). The only hospitalizations during
this project were those who were diagnosed and treated for (4) pneumonia, CHF, and COPD.
The hospitalization rate for this project was 0.727% (Table 7).
A larger sample size of cases would have been better for this project for each of the 4
groups mentioned in the previous paragraph. However, this project seems to indicate that NH
residents can be effectively treated for pneumonia alone, pneumonia and CHF, and pneumonia
and COPD cases. Even in those who have pneumonia, CHF, and COPD, hospitalization may be
preventable. Of the five who were diagnosed and treated with pneumonia, CHF, and COPD, 1
was hospitalized and died, another went to the hospital for 1.5 days, and the other 3 remained in
the NH. The protocol in this study seems to indicate that even if a NH resident goes to the
hospital after diagnosis and treatment in the NH the length of stay at the hospital can be
shortened due to patient’s health improvement.
APPLICATION TO PRACTICE
Barriers and Cost
The nurse practitioner led quality improvement project may reduce hospitalizations due
to pneumonia from the nursing home setting. The barriers to this project were as follow. It was
difficult to implement the primary prevention aspect of this protocol because the time this project
was initiated was not in season for flu vaccine. There is a preference to vaccinate for pneumonia
and influenza during the flu season. At the NH that participated in this project, there was no
issue with the care being provided for by the NPs. However, the leadership in other nursing
homes may not be willing to let NPs take control of the care for their residents. Other clinical
18
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practitioners who were part of this project did not oppose the NPs. However, other clinical
practitioners may not want to have a NP directing the monitoring, diagnoses, treatment, and
prescriptions for patients under their care.
The NH staff that participated in this project cooperated very much. However, nursing
home staff providing direct care to the patients in other nursing homes may be overburdened
with addition of tasks. For example, they may not be so willing to contact the resident and/or
decision makers for patients regarding vaccinations. Patients and/or their respective family
members may be unwilling to participate in this project. Some patients may be under
guardianship and the guardians do not consent or are unreachable. Managed care insurance
companies may also be unwilling to participate although that was not the case with this project.
The NPs and nursing home staff that participated in this study were not an additional cost
since they are already employed to provide services to the patients in the nursing homes. All
medicines, diagnostic services and vaccines suggested in this protocol were paid for by the
managed cared care company(ies). With implementation of this evidence-based clinical
protocol, the cost of treating NH residents in the NH rather than at the hospital was considerably
less. The project itself lasted 10 weeks. There were not as many case as was desired.
Providing care to patients with a critical condition complicated by co-morbidities at the
hospital will easily consume the financial reimbursement provided to all stakeholders. It is
estimated that each hospitalization costs around $9,300 (Pfuntner et al, 2013). Regardless of the
setting (hospital or nursing home), providing care to the patient will require diagnostic,
pharmaceutical, custodial, nursing, and medical care which the managed care companies are
obligated to pay. However, providing care at the nursing home costs considerably less due to
care being provided at a facility that is not as expensive as that of a hospital.
19
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FEASIBILITY
This protocol is extremely feasible. Only very extreme cases of pneumonia need to be
treated at the hospital. The NH must have the following: provision of proper nursing care to its
residents (patient assessment, care, intravenous insertion for medical treatment), intravenous
supplies, access to diagnostic suppliers (chest x ray and laboratory), and pharmacy supplies. The
NPs need to practice the protocol daily. And the payers need to accept providing payment for
services rendered at the NH by all who are providing them.
CONCLUSION
Evidence based NP led care using the protocol in this project resulted in effective
diagnosis and treatment of NH residents in the NH setting when dealing with pneumonia, CHF,
and COPD as evidenced by a very low hospitalization rate: 0.72% tracked for 3 months. The
NH residents have many stressors and weak defenses. Providing the care proposed in this
protocol alleviates some of the stresses on the residents and provides the strength to resist disease
and promote health.

20
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APPENDIX A

PNEUMONIA PROTOCOL FOR NURSE PRACTITIONERS
In Nursing Home Setting
PRIMARY PREVENTION OF PNEUMONIA INCIDENCE
Bertha Carrion, ARNP used guidelines from Mandell, Wunderink, Anzueto, Bartlett, Campbell, Dean, Dowell, File,
Musher, Niederman, Torres, & Whitney (2007) as primary resource to develop this protocol. For routine
pneumococcal vaccination, Bertha Carrion used the pneumococcal vaccine timing for adults recommendations from
the Centers for Disease Control (CDC).
Routine Pneumococcal Vaccination (Pneumococcal Vaccine Timing for Adults, CDC, 2015)
• According to CDC, 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar13) and 23-valent
pneumococcal polysaccharide vaccine (PPSV23, Pneumovax23) are the two vaccines recommended for adults.
• One PCV13 dose is to be given to adults 65 years or older if the adult has never gotten PCV13.
PCV13 and PPSV23 should never be given at the same time.
• If an adult aged 65 years or older has gotten the PPSV23 and not the PCV13, then PCV 13 should be given at
least 1 year after the PPSV23 was given.
• If an adult 65 years or older has never received pneumonia vaccine or the history is unknown, then PCV13
should be given first followed by PPSV23 at least 1 year after receiving the PCV13 for adults with
immunocompetent conditions (alcoholism, chronic heart disease, chronic liver disease, chronic lung disease,
cigarette smoking, diabetes mellitus), cochlear implants or cerebrospinal (CSF) fluid leaks. If however an adult
has immunocompromising conditions (chronic renal failure, immunodeficiency, malignancy, HIV, Hodgkin
disease, iatrogenic immunosuppression, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, or solid
organ transplant) or asplenia (congenital or acquired asplenia, sicke cell disease, other hemoglobinopathies),
then the patient should receive the follow-up PPSV23 8 weeks after PCV13 instead of at least 1 year after.
After adult over 65 years of age receives PPSV23, the adult should receive another dose of PPSV23. PCV13
should not be given to adults over 65 years of age if adult has received before turning 65 years old.
• Adults aged 19-64 who have chronic heart disease, lung disease, diabetes mellitus, alcoholism, smoking
cigarette habit and/or chronic liver disease should receive one dose of PPSV23 followed by one dose of PCV13
when aged 65 years and after at least 1 year of having received the PPSV23. One final dose of PPSV23 should
be given at age 65 and older after one year of having received the PCV13 and after 5 years of having received
the previous PPSV23.
• Adults aged 19-64 with CSF leaks, cochlear implants, sickle cell disease or other hemoglobinopathies,
congenital or acquired asplenia, congenital or acquired immunodeficiencies, HIV infection, chronic renal
failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, iatrogenic
immunosuppression, solid organ transplant, and/or multiple myeloma should receive one dose of PCV13
followed by PPSV23 after at least 8 weeks of having received the PCV13. After five years, these adults should
receive a second dose of PPSV23 but not if patient has CSF leaks or cochlear implants. Upon these adults
turning 65 years, one final dose of PPSV23 should be given after at least 5 years have passed from previous
PPSV dose.
Routine Influenza Vaccination
The flu vaccine should be offered to all persons over 50 years old (innactivated virus influenza- injection)
yearly. High-risk groups such as patients with diabetes, heart disease, CKD, respiratory chronic conditions,
alcoholism, asplenia, immunocompromising disorders and residents of long-term care facilities are candidates
for influenza vaccine yearly. Health care workers and healthy persons in contact with high-risk population
should have the influenza vaccine yearly unless contraindicated.
Live attenuated influenza vaccine (intranasal spray) should not be given to patients with asthma, chronic
pulmonary disease, cardiovascular disease, asplenia, or immunocompromising disorders.
Respiratory Hygiene Measures
Hand washing, masks, tissues, for patients with cough should be used at all times to avoid spread of respiratory
infections (CDC, 2007).
Smoking Cessation
Patients who use tobacco should be offered smoking cessation treatment.
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SECONDARY PREVENTION OF PNEUMONIA INCIDENCE
Early interventions are the key to successful treatment and prevention of possible complications and even death
when a patient is affected with pneumonia. Identification of early signs can make a difference.
Early Signs of Pneumonia
During the first week, patients with pneumonia may have the following: cough, weakness,
complaints of not feeling well, decreased appetite, wet cough, increased confusion, and chills.
Second Set of Symptoms
Patients demonstrating a second set of symptoms (fever, dyspnea, chest pain, agitation, nausea and vomiting)
usually experience mayor changes in status. During this stage, nursing home staff will usually call the nurse
practitioner, physician assistant or medical doctor.
Initial Communication of Patient’s Change of Status
Upon receiving notification from the nursing home staff, the nurse practitioner (NP) should assure them of
proper attention to be given right away. The NP should communicate with collaborative physician concerning
the patient’s condition and treatment intent with invitation for physician to modify or provide input upon
assessing patient.

Nurse Practitioner Assessment
The patient needs to be seen and assessed with review of multiple organs system response to acute
illness. The NP should visually assess the patient. How does the patient look? Does the patient seem to be
toxic? Does it look like a common cold or something more severe?
NP should assess the lung for evidence of crackles, ronchi, rales, wheezing, use of accessory muscles for
respiration, low O2, cough, decreased breath sounds, dyspnea, chest pain, and sputum production. Both clinical
features and physical exam findings may be lacking or altered in the elderly. Upon using the pulse oximeter,
oxygen saturation may be low. Consider 02 supplement to be started immediately. When examining the
patient’s vital signs the NP should observe whether or not the patient has hypotension, fever, hyperglycemia,
hypoglycemia, or diaphoresis.
Differential Diagnoses
The NP should review different patient’s chronic co-morbidities that need to be taken into consideration such as
CHF, COPD, bronchitis, aspiration, pulmonary fibrosis, pulmonary emboli and asthma. In this study, the focus
concerning differential diagnoses will be on CHF and COPD.
Determining using Nursing Home Pneumonia Severity Criteria
If CXR shows lobal and multilobal infiltrates in lungs and
patient has 1 of the following pneumonia symptoms, patient is moderate.
patient has 2 of the following pneumonia symptoms, patient is moderate to severe.
patient has 3 of the following symptoms, patient is severe.
Pneumonia Symptoms
Respiratory rate ≥30 breath/mins
AMS: increased confusion/disorientation/lethargy
Hypoxemia
Leukocythosis/leukopenia
Uremia: BUN elevated ≥20- High risk >40
HypotensionThrombocytopenia
Hypothermia/Hyperthermia

Nurse Practitioner’s Plan of Care
Pretreatment:
Stat blood cultures: Blood cultures should be obtained before antibiotic is started. Blood cultures are
recommended for all patients with severe CAP because of higher yield and greater possibility of the presence of
pathogens not being covered by the usual empirical therapy and the potential to affect antibiotic management.
Stat CBC, CMP, BNP for baseline.
Sputum culture: a sputum sample for stain and culture should be done only if good specimen can be obtained.
40% or more of patients are unable to produce any sputum or produce sputum in a timely manner.
Stat Chest X-Ray (CXR): anterior, posterior and lateral should be ordered.
A positive CXR with infiltrates with or without supporting microbial data is required for the diagnosis of
pneumonia. At times, the patient may have pneumonia but not be evident in CXR. For patients that present
with suspected pneumonia but have negative CXR findings, it may be reasonable to treat their condition and
repeat CXR in 24 to 48 hrs
Stat Urinalysis (UA) with culture and sensitivity: Many elderly have chronic UTIs. Straight catheter should
be used to obtain urine if a clean specimen is not possible for dementia patients.
Urinary Antigens Test (optional for Legionella pneumophila and Streptococcus pneumonia)
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Influenza AB Test: May lead to consideration of treatment for antiviral therapy.

Intervention as Prescribed in Nurse Practitioner’s Plan of Care
Initial Medical Treatment:
Obtain IV site.
IV fluids should be started immediately to hydrate the patient. No labs results should be waited on to start IV
fluids maintenance (0.9 % NS at 50 to 65 cc/hour, even with CHF patients).
Oxygenation of patient should be started as well, O2 at 2L NC.
Empiric antibiotics should start right after blood and urine samples are collected. Do not wait for lab results.
The goal is the eradication of the affecting organism with resultant resolution of clinical disease. The selection
of antimicrobial therapy is based on prediction of most likely pathogens and susceptibility patterns.
Recommendations are generally for a class of antibiotics rather than a specific drug.
Delay in starting antibiotic therapy from the need to obtain specimens should be prevented at all cost.
Only encourage diagnostic testing (i.e. sputum) if the result is likely to change individual antibiotic
management.
Nursing Home patients may have multiple comorbidities (CKD, DM, CHF, COPD, Hypertensive Heart disease,
malignancies, use of immunosuppressant drugs), or use of antimicrobial drug within the previous 3 months.
See which antibiotic they used and use appropriate antibiotic treatment (preferred or alternative).
Initial Recommended Empirical Antibiotic Therapy
Respiratory Fluoroquinolones:
Levofloxacin 750 mg
Ciprofloxacin 750 mg IV
B-Lactam:
Ceftriaxone 1-2 gm IV daily
Cefepime 1GM IV daily
Zozyn 3.375 GM IV q 8 hrs,
Meropenem 1 Gm q 8 hrs
Imipenem 500 mg q 6-8 HRs IV daily
Current levels of B-Lactam resistance does not result in failure when appropriate agents and proper doses are
used.
Moderate Pneumonia:
Beta-Lactam (Ceftriaxone, Cefepime) + Respiratory Fluoroquinolone (moxifloxacin, gemifloxacin or
Levofloxacin) + Macrolides (There is a rise in resistance to macrolides).
Severe Pneumonia:
Beta-Lactam (Cefepime, Zozyn, Imipenem) + a respiratory Fluoroquinolone + Azithromycin, (an alternative to
Azithromycin is Doxycycline(weak recommendation) ).
Special concerns:
Pseudomonas: Beta Lactam antipseudomonal + Levofloxacin 750 mg or Ciprofloxacin 750 mg IV
Or
B- Lactam plus aminoglycoside + azithromycin (strong recommendation)
Or
B- Lactam + antipneumoccocal fluoroquinolone and aminoglycoside (moderate recommendation)
If MRSA is a consideration: B- Lactam + Vancomycin
Switch to Oral therapy: Patient can be switched to oral therapy when hemodynamically stable.
Able to swallow medications No fever for 48 hrs
HR <100beats/min
Respiratory rate
<24 b/min
BP within normal range
O2 sat >90% at RA
Baseline mental status
Most common organisms affecting special populations
On COPD patients suspect: Pseudomonas Aeruginosa, S. Pneumonia, H. Influenzae, Moraxella Cararrhalis
Aspiration suspect: Gram negative enteric pathogens and Oral anaerobes (E. Coli,Pseudomonas Aeruginosa,
Klebsiella)
Structural Lung Disease: Suspect: Pseudomonas Aeruginosa, Klebsiella, S, Aureus, S. Pneumoniae.
Pathogen Directed Therapy. Refer to PNEUMONIA PATHOGEN DIRECTED TREATMENT table
Hospitalization: Consider transfer to hospital if oxygenation is less that 85% with oxygen supplement and/or
severe hypotension is not improving even upon receiving bolus of IV fluids (250 to 500 cc bolus).inability to
maintain oral intake, and severe change in mental status or increased deterioration after 72 hours of treatment.
But, even at the ICU the failure to treatment and mortality rate may be as high as 49% risk of death.
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TERTIARY PREVENTION OF PNEUMONIA INCIDENCE
Non responding pneumonia is used to define an inadequate clinical response despite antibiotic therapy.
Upon arriving from the hospital and/or initiating secondary prevention of pneumonia, NP will follow-up with patient
and others on days 1, 3, 7, 10, 14, 21, 28, and 30 after patient arriving from the hospital and/or initiating secondary
prevention of pneumonia. Upon patient reaching
Possible Complications:
Persistent Infiltrates in CXR.
Persistent fever after 1-2 days of treatment or recurring at day 7of Treatment.
Usually the patient develops the following etiology:
Failure to improve
early <72 hrs of Treatment
Delayed>72 hrs-uncovered pathogen-parapneumonic effusion/empyema/new organism such as nosocomial
infection
Extrapulmonary- noninfectious/PE/CHF
Nonresolving or slow resolving pneumonia >30 days:
Persistent infiltrates >30 days of initial pneumonia like symptoms.
Factors associated with nonresponding pneumonia:
>65 years old
Pleural efussion
Multilobar infitrates
Cavitation
Leukopenia
Gram negative pneumonia
Legionella pneumonia
EVALUATION
Management of nonresponding pneumonia:
Monitor response to treatment daily: Assess patient daily.
Remenber; it may be an inadequate host response, not necessarily wrong therapy.
Monitor: COPD, CHF, CKD, Autoinmune disorders, ARDS
Steps to respond to nonresponding pneumonia: Contingency plan:
Reevaluate initial microbiological results.
Repeat Blood cultures for deterioration or progressive pneumonia
Rapid urinary antigens/UA
It is recommended to do a CXR, CBC, CMP q 2 days during therapy to evaluate response to antibiotic therapy.
If persistent Infiltrates, suspect CHF /peural efussion/chronic aspiration.
Chest CT may be needed to rule out pulmonary emboli/pleural efussion/lung abscess/CHF.
Non response may also be mimicked by conmitant extrapulmonary infection such as UTI, skin infection/chronic
aspiration/and colonization of antibiotic resistant microorganisms such as MRSA or Pseudomonas.
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NEUMONIA PATHOGEN DIRECTED TREATMENT
Streptococcus Pneumonia
(Penicillin nonresistant; MIC <2 mg/mL)
Preferred: Penicillin G or Amoxicillin.
Alternative: Oral Cephalosporins (Cefpodoxime,
Cefprozil, Cefuroxime, Cefdinir, Cefditoren) or
parenteral Cephalosporins (Cefuroxime, Ceftriaxone,
Cefotaxime), Clindamycin, Doxycyline, respiratory
Fluoroquinolone.
Streptococcus Pneumonia
(Penicillin resistant; MIC ≥2 mg/mL)
Preferred: Cefotaxime, Ceftriaxone, or
Fluoroquinolone.
Alternative: Vancomycin, Linezolid, high-dose
Amoxicillin (3 g/day with Penicillin MIC ≤4 mg/mL)
Haemophilus Influenza (Non–b-lactamase producing)
Preferred: Amoxicillin.
Alternative: Fluoroquinolone.
Haemophilus Influenza (b-Lactamase producing)
Preferred: second- or third-generation Cephalosporin
or Amoxicillin-Clavulanate
Alternative: Fluoroquinolone.
Mycoplasma or Chlamydophila Pneumoniae
Preferred: Tetracycline.
Alternative: Fluoroquinolone.
Legionella Species
Preferred: Fluoroquinolone.
Alternative:
Chlamydophila Psittaci or Coxiella Burnetii
Preferred: Tetracycline.
Alternative:
Francisella Tularensis
Preferred:
Alternative: Gentamicin or Streptomycin
Yersinisa Pestis
Preferred: Streptomycin or Gentamicin.
Alternative: Fluoroquinolone.
Bacillus Anthracis (inhalation)
Preferred: Ciprofloxacin, Levofloxacin,
Doxycycline (usually with second agent).
Alternative: other Fluoroquinolones, B-Lactam, if
susceptible, Rifampin, Clindamycin or
Chloramphenicol.
Enterobacteriaceae
Preferred: Third-generation Cephalosporin or
Carbapenem (drug of choice if extended-spectrum blactamase producer).
Alternative: B-Lactam/B-Lactamase Inhibitor or
Fluoroquinolone
Histoplasmosis or Blastomycosis
Preferred: Itraconazole.
Alternative: Amphotericin B.
Pseudomonas Aeruginosa

Preferred: Antipseudomonal B-Lactame plus
(Ciprofloxacin or Levofloxacin or Aminoglycoside).
Alternative: Aminoglycoside plus (Ciprofloxacin or
Levofloxacin).
Burkholderia Pseudomallei,
Preferred: Carbapenem or ceftazadime.
Alternative: Fluoroquinolone.
Acinetobacter Species
Preferred: Carbapenem.
Alternative: Cephalosporin-Aminoglycoside,
Ampicillinsulbactam, or Colistin.
Staphylococcus Aureus (Methicillin susceptible)
Preferred: Antistaphylococcal Penicillin.
Alternative: Cefazolin or Clindamycin
Staphylococcus Aureus (Methicillin resistant)
Preferred: Vancomycin or Linezolid.
Alternative:
Bordetella Pertussis
Preferred: Macrolide
Alternative:
Anaerobe (aspiration)
Preferred: b-Lactam/b-lactamase inhibitor,
clindamycin.
Alternative: Carbapenem
Influenza virus
Preferred: Oseltamivir or Zanamivir.
Mycobacterium Tuberculosis
Preferred: Isoniazid plus rifampin plus ethambutol
plus pyrazinamide.
Alternative: refer to other guidelines for controlling
tuberculosis in the United States (American Thoracic
Society, Centers for Disease Control and Prevention, et
al., 2005)
Coccidioides species
Preferred: no therapy recommended for normal host
with uncomplicated infection. If therapy is needed, the
preferred antimicrobial therapy is itraconazole or
fluconazole.
Alternative: Amphotericin B
For more information, you may refer to
Mandell, Wunderink, Anzueto, Bartlett, Campbell, Dean,
Dowell, File, Musher, Niederman, Torres, & Whitney
(2007) Infectious Diseases Society of America/American
Thoracic Society Consensus Guidelines on the
Management of Community-Acquired Pneumonia in
Adults. Clinical Infectious Diseases; 44:S27-72.
CDC, 2015. Pneumococcal Vaccine Timing for Adults.
Retrieved from http://www.cdc.gov/vaccines/vpdvac/pneumo/downloads/adult-vax-clinician-aid.pdf on
March 2
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APPENDIX B
PRIMARY PREVENTION: PNEUMOCOCCAL VACCINE
Pneumococcal Vaccine History
PATIENT NAME
ARNP

NURSING HOME
DATE
W
B
AI
A NH

RACE
ETHNICITY

M

PR

CU

HA

JA

O

Y

N

O

Hispanic
Carribean

Is history for patient available for the last 12 months?
If not, how many months of history is available for this patient?
Are pneumococcal vaccines contraindicated for this patient?
Does the patient now use tobacco products?
Did the patient use tobacco products in the past?
Does the patient have immunocompromising conditions?
How many acute pneumonia incidents in the past year?
How many hospitalizations due to pneumonia in the past year?
COPD

Asthma CHF

Which of the following chronic conditions does the patient have?
PNEUMOCOCCAL VACCINATIONS RECEIVED IN THE PAST
INITIAL DOSE
DATE
AGE
PCV 13
PPSV 23
Other
FOLLOW UP DOSE(S)
DATE
AGE
PCV 13
PPSV 23
Other
PNEUMOCOCCAL VACCINE ORDERS DURING PROJECT
Did patient receive any vaccination during project?
PCV 13
PPSV23
PPSV23
What pneumonia vaccine(s) is patient to receive and when?
PCV 13
PPSV23
PPSV23

Y

N

DATE

Y

N

DATE
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APPENDIX C
PNEUMOCOCCAL VACCINE ADMINISTRATION PROTOCOL
PATIENTS ≥65 YEARS OLD WHO NEVER RECEIVED PNEUMOCOCCAL VACCINE
PCV13

PPSV23

≥8 weeks or
> 1 year after initial PCV13
PPSV23 is to be administered ≥8 weeks from date PCV13 was administered
for patients with immunocompromising conditions, functional or anatomic
asplenia, cerebrospinal fluid leaks, or cochlear implants
If not received at 8 weeks, then PPSV23 is to be administered at least 1 year
after initial PCV13 vaccination.
PATIENTS WHO HAVED RECEIVED PPSV23 AT ≥65 YEARS OLD
PPSV23
Received
at ≥65

PCV13

≥1 year
PCV13 is to be administered ≥ 1 years from when PPSV23 was administered.
PATIENTS WHO HAVED RECEIVED PPSV23 AT <65 YEARS OLD
AND ARE CURRENTLY ≥65 YEARS OLD
PPSV23
Received
<65

PCV13 at
≥65
≥1 year

PPSV23

≥1 year
≥5 years

PCV13 is to be administered ≥ 1 years from when PPSV23 was administered ≥65.
PPSV23 is to be administered ≥ 1 year after PCV13 vaccination.
PPSV23 is to be administered ≥ 5 years after most recent PPSV23 vaccination.
From Advisory Committee on Immunization Practices, United States (Tomczyk et al, 2014)
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APPENDIX D
PRIMARY PREVENTION: INFLUENZA VACCINE
Influenza Vaccine History
PATIENT NAME
ARNP

NURSING HOME
DATE
Y

N

Has patient received the influenza vaccine this year?
Has patient experienced a serious systemic or anaphylactic reaction to influenza
Is patient in the present experiencing moderate or severe acute illness?
Does the patient have history of Guillain Barré syndrome within 6 weeks of a previous
Is receiving this vaccine contraindicated for this patient?
Has patient received the vaccine information statement?
INFLUENZA VACCINE RECORD

Date administered

Manufacturer & Lot Number

Vaccination Site and
Route

Name and title of
person administering vaccine

Publication Date of the VIS is
and was given to patient on
If patient did not receive the vaccine, please state reason:
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APPENDIX E
INFLUENZA VACCINE ADMINISTRATION PROTOCOL
Administer the Influenza Vaccine to Patient in the Nursing Home Who Meets Following Criteria
1) Has not received the influenza vaccine this year
2) Has not experienced a serious systemic or anaphylactic reaction to influenza vaccine or
any of its components
3) Is not at the present time experiencing moderate or severe acute illness
4) Does not have history of Guillain Barré syndrome within 6 weeks of a previous influenza
vaccination
Administer 0.5 mL of IIV-high dose intramuscular in deltoid muscle using needle gauge 22-25
and making adjustments according to the following table.
GENDER AND WEIGHT OF NEEDLE
GENDER AND WEIGHT
NEEDLE
PATIENT
LENGTH
OF PATIENT
LENGTH
Female or male less than 130 lbs ⅝”- 1”
Male 153-260 lbs
1-1½”
Female or male 130-152 lbs
1”
Female 200+ lbs
1½”
Female 153-200 lbs
1-1½”
Male 260+
1½”
Update medical records. Be ready to medically manage vaccine reactions in adults.
http://www.immunize.org/catg.d/p3082.pdf
Report All Adverse Events to Vaccine Adverse Event Reporting System (VAERS) at
www.vaers.hhs.gov.
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APPENDIX F
Nursing Home Staff and Multidisciplinary Team
Prevention and Surveillance of Pneumonia
Prevention is best nursing practice. Expand the patient’s line of defense.
Educate all involved in the decision making of the patient’s health concerning pneumonia and
influenza vaccination (Appendices C-E as well as vaccination information sheets).
Vaccinate patients with Influenza Vaccine and Pneumococcal Vaccine as ordered.
Early detection is also best nursing practice.
All nursing home staff and clinicians should together watch patients’ development of these
symptoms. The nursing home staff should notify the nurse practitioner concerning patient
development of these symptoms. And the nurse practitioner ought to be checking
continuously own patients for development of these symptoms.
Recognize early signs of pneumonia.
___Cough
___Weakness ___ Complains of not feeling well
___Decreased appetite
___Chills
___ Increased confusion

___Wet cough

Recognize worsening patient condition.
___Fever
___Dyspnea ___Chest Pain ___Agitation ___Nausea and vomiting
Recognize very critical clinical condition of patient.
___Respiratory rate ≥30 breaths per minute ___ PaO2/FiO2 at ≤250___O2 saturation <90%
___PaO2 <60 mmHg ___<36° Celsius
___≥38° Celsius
___Tachycardia ≥125 bpm
___Blood Pressure D≤60 and/or S≤90
___Weight Gain (3 lbs in 1 day or 5 lbs in 1 week)
___Decreased breath sounds on auscultation
Call the Nurse Practitioner providing the care for the patients enrolled in this program
whenever signs of possible pneumonia incidence are exhibited by patient(s) before, during and
after initiation of any treatments for pneumonia.
Follow the orders given by the NP.
Report any continued progress or worsening of health condition of patient to the NP at all
times.
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APPENDIX G
SECONDARY PREVENTION: NURSE PRACTITIONER ASSESSMENT OF PATIENT
PATIENT NAME
ARNP NAME

NURSING HOME
DATE
PHYSICAL ASSESSMENT

How does the patient look?
Y
Does the patient seem to be toxic?
Does it look like a common cold?
Does it look like something more severe than a common cold?
Are there any of following symptoms/signs?
Crackles
Ronchi
Rales
Wheezing

Low O2

Cough
Dyspnea
Chest Pain
Dyspnea
Use of accessory muscles for respiration
Sputum Production
Fever
Hypotension
Hyperglycemia
Hypoglycemia
Does patient have History of any of the following?
CHF
COPD
Pulmonary Fibrosis
Asthma
ASSESSMENT
Y
Y
Swelling in Abdomen
Neck Vein Distension
Confusion
Cough w/o phlegm
Cough w/ phlegm
Multilobar Infiltrates
Respiratory Rate
≥30 breaths per minute
PaO2 /FiO2

≤250

O2 saturation or

<90

PaO2

<60
3 lbs in 1 day or 5 lbs in week

Weight Gain
Temperature
Temperature
Blood Pressure
Tachycardia
BUN level

Y

<36° Celsius
≥38° Celsius
D≤60 and/or S≤90
≥125 bpm

≥20 mg/dL
3

WBC count

<4000 cells/mm

WBC count

≥14,000 cells/mm3

Neutrophils

>90%

Platelet count

<100,000 cells/mm
<35g/L

Albumin
Pathogen

N

3

Which One?
INITIAL DIAGNOSIS Pneumonia
COPD

CHF

Other

Pneumonia Nursing Home Severity Index
Moderate
Moderate-Severe
Severe
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PNEUMONIA NURSING HOME SEVERITY INDEX
CXR shows lobal and multilobal infiltrates in lungs
and patient has 1 of the following pneumonia symptoms
Moderate to Severe
CXR shows lobal and multilobal infiltrates in lungs
and patient has 2 of the following pneumonia symptoms
Severe
CXR shows lobal and multilobal infiltrates in lungs
and patient has 3 of the following symptoms.
PNEUMONIA SYMPTOMS CHECKLIST
Moderate

Respiratory Rate
≥30 breaths/min
PaO2/FiO2
≤250
Confusion/disorientation
Uremia (BUN level, ≥20 mg/dL)
Leukopenia (WBC count, <4000 cells/mm3)
Leukocytosis (WBC count ≥14,000 cells/mm3)
Thrombocytopenia (platelet count, <100,000 cells/mm3 )
Hypothermia (core temperature, <36° Celsius)
Systolic BP <90 mmHg
Diastolic BP ≤60 mmHg
Hypotension requiring aggressive fluid resuscitation

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

N
N
N
N
N
N
N
N
N
N
N

INFILTRATES AND/OR PATHOGEN CHECK
Chest X-Ray
PN or CHF
Streptococcus pneumonia
Enterobacteriaceae
Mycoplasma pneumonia
Influenza A & B
Haeophilus influenza
Adenovirus
Chlamydophilia psittaci
Respiratory syncytial virus
Legionella
Parainfluenza
Coxiella burneti
Aspiration/Anaerobe
Francesca tularensis
Staphylococcus aureus
Yersina pestis
Gram-negative bacilli
Bacillus anthracis
Pseudomonas aeruginosa
Burkholderia pseudomallei
Acinetobacter species
Bordetella pertussis
Myobacterium tuberculosis
Coccidioides species
Histoplasmosis
Blastomycosis

40

SCHOLARLY QUALITY IMPROVEMENT PROJECT TO REDUCE HOSPITALIZATION
APPENDIX H
NURSE PRACTITIONER PLAN OF CARE INTERVENTION NOTE DURING SECONDARY PREVENTION
PATIENT NAME
NURSING HOME
ARNP NAME
DATE
ORDERS
Stat CBC
CMP
BNP
Sputum culture
UA test
Stat CXR anterior, posterior, and lateral
Influenza Test
Repeat CXR in 24-48 hours if indicated
Stat UA with culture sensitivity
Obtain IV site
Start IV fluids
Oxygenate patient
Empiric antibiotics
MEDICINE ORDERED
Respiratory Fluoquinolones
β -Lactam
Aminoglycoside
Switch to Oral Therapy when patient meets the following requirements
Able to swallow medications
No fever for 48 hrs
HR <100 beats/min
Respiratory rate <24 b/min
BP within normal range
O2 sat >90% at RA
Baseline mental status
Contact NP should pneumonia patient conditions worsen.
CONTINUE MEDICATION
STOP ALL MEDICATION
ALTER MEDICATION
Stop Medication previously ordered and change to the following:
Respiratory Fluoquinolones
β -Lactam
Aminoglycoside
Hospitalize patient if any of the following occur:
O2 <87% with O2 supplement and/or severe hypotension even after receiving 250-500 cc bolus of IV fluids
Inability to maintain oral intake
Severe change in mental status
Increased deterioration after 72 hours of treatment
Specific Pathogen Identified
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APPENDIX I
TERTIARY PREVENTION OF PNEUMONIA INCIDENCE: ASSESSMENT AND PLAN OF CARE
PATIENT NAME
ARNP NAME
DAYS AFTER START OF THERAPY
OR RETURN FROM HOSPITAL

NURSING HOME
DATE
1
21

3
28

7
30

10

14
Y

N

Has patient improved within the first 72 hours of treatment?
Are there any of following symptoms/signs?
Crackles
Ronchi
Rales

Wheezing

Low O2

Cough
Dyspnea
Cough & phlegm
Chest Pain
Dyspnea
COPD
CHF
Use of accessory muscles for respiration
Sputum
Infiltrates
Pneumonia
Pleural Effusion
Cavitation
Fever
Hypotension
Hyperglycemia
Hypoglemia
Leukopenia
Legionella pneumonia
Gram negative penuemonia
Hyperventilation
Weight Gain
Low Diastolic
Low Systolic
Tachycardia
High BUN
Low WBC count
High WBC count
High Neutrophils
Low Albumin
Low platelet count
ORDERS
Stat CBC
CMP
BNP
Sputum culture
UA
Stat CXR anterior, posterior, and lateral
Influenza Test
Repeat CXR in 24-48 hours if indicated
Stat UA with culture sensitivity
Obtain IV site
Start IV fluids
Oxygenate patient
Empiric antibiotics
Chest CT
CONTINUE MEDICATION
STOP MEDICATION
ALTER MEDICATION
Stop Medication previously ordered and change to the following:
Respiratory Fluoquinolone
β -Lactam
Aminoglycoside
Hospitalize patient if any of the following occur:
O2 <87% with O2 supplement and/or severe hypotension even after receiving 250-500 cc bolus of IV fluids
Inability to maintain oral intake
Severe change in mental status
Increased deterioration after 72 hours of treatment
SPECIFIC PATHOGEN IDENTIFIED:
DIAGNOSIS
Pneumonia
COPD
CHF
Other
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APPENDIX J: DIFFERENTIAL DIAGNOSIS OF PNEUMONIA PROTOCOL FOR COPD

COPD is a progressive disease state with airflow limitation that is not fully reversible.
ASSESSMENT
Recognize risk factors by asking about personal history of patient such as history of smoking, second
hand smoking, worked in areas of much air pollution, and Alpha-1 antitrypsin deficiency, Northern
European ancestry and occupation in high risk of pulmonary hazard.
Evaluate signs/symptoms as to indicators that patient may be experiencing a COPD exacerbation:
dyspnea, chronic cough, increased chronic sputum production, increased purulence of sputum, phlegm,
lacking energy, tight chest, lacking breath, and hyperinflation.
Find out how many COPD exacerbations or hospitalizations due to COPD the patient has experienced
in the past year.
Using the Pulmonary function test determine whether patient is GOLD 1, 2, 3, or 4.
.
PULMONARY FUNCTION TEST (GOLD)
STAGE
FEV1/
MEASUREMENT
FVC
Normal
≥70%
>80%
GOLD 1 Mild
<70%
≥80% of predicted value
GOLD 2 Moderate
<70%
50% ≤ FEV1 <80% of predicted value
GOLD 3 Severe
<70%
30% ≤ FEV1 <50% of predicted value
GOLD 4 Very Severe/End Stage
<70%
<30% FEV1 of predicted value
FEV1 = forced expiratory volume in one second
FVC = forced vital capacity GOLD = Global Initiative for Chronic Obstructive Lung
Disease
The GOLD Treatment guidelines uses combined COPD assessment approach to group patients according to symptoms, airflow limitation and
risk for exacerbations. Symptoms are assessed using Modified British Medical Research council (mMRC) or COPD assessment test (CAT) scale.

Using the COPD Risk Classification determine whether the patient has more or less symptoms of
COPD
COPD RISK CLASSIFICATION
Patient
COPD exacerbations
COPD Hospitalizations
mMRC
CAT
Symptoms
Group
past year
past year
Group A:
≤1
0
0, 1
<10
Less
Low Risk
Group B:
≤1
0
≥2
≥10
More
Low Risk
Group C:
≥2
≥1
0, 1
<10
Less
High Risk
Group D:
≥2
≥1
≥2
≥10
More
High Risk
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NP PLAN OF CARE

Order or perform tests to aid in the diagnosis of COPD or not as appropriate to patient’s condition:
pulmonary function test, Spirometry, Pulse Oximetry, CXR, ECG, ABG, CBC, and/ or BMP.
Treatment Options
• Oxygen- Goal 88 to 92% 2L nasal cannula
• Bronchodilators:
short acting inhaled Beta2-agonist with or without short acting anticholinergic are preferred: Duoneb
(albuterol/ipratropium 0.5/2.5/3mls q 6 hrs via nev) and Pulmicort BiD.
• Systemic Corticosteroids: Shorten recovery time, improve lung function (FEV1) and arterial
Hypoxemia (PaO2) and reduce risk for early relapse, treatment failure and length of hospital stay.
First choice: Solumedrol 125 mg IM x1, then 80 mg IM x 1 dose, then 40 mg IM x1. Consider to start
Prednisone 40 mg PO q day x 5 days recommended.
Second option: Medrol pak 4 mg as directed.
• Antibiotic therapy should be given to patients with:
Increased dyspnea
Increased sputum volume
Increased sputum purulence
Who requires mechanical ventilation
Possible complications of COPD
Cor Pulmonare
Mechanical Ventilation and ventilator associated pneumonia
Antibiotic-related diarrhea-Provide Probiotic therapy while giving antibiotic therapy.
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APPENDIX K
SECONDARY & TERTIARY PREVENTION COPD ASSESSMENT AND PLAN OF CARE
PATIENT NAME
NURSING HOME
ARNP NAME
DATE
PHYSICAL ASSESSMENT
History of smoking
Second of hand smoking
Worked in areas of much air pollution
Alpha-1 antitrypsin deficiency
Northern European ancestry
Occupation in high risk of pulmonary hazard
SIGNS/SYMPTOMS
Dyspnea
Chronic Cough
Phlegm
Tight Chest
Lacking energy
Lacking breath
Hyperinflation
Increased chronic sputum poduction
Increased purulence of sputum
COPD INCIDENTS THROUGHOUT LAST YEAR
Hospitalization due to COPD p/year
0-1 exacerbations
1-2 exacerbations
≥2 exacerbations p/year
TESTS TO ORDER OR PERFORM
Pulmonary function test
Spirometry
Pulse Oximetry
CXR
ECG
ABG
CBC
BNP
GOLD STAGE:
Normal
1
2
3
4
SYMPTOMS:
More
Less
TREATMENT ORDERS
O2 : 88-92% 2L Nasal Cannula
Bronchodilators:
Duoneb (albuterol/ipratropium 0.5/2.5/3mls q 6 hrs via nev) and Pulmicort BiD
Systemic Corticosteroids
Solumedrol 125 mg IM x1, then 80 mg IM x 1 dose, then 40 mg IM x1
Prednisone 40 mg PO q day x 5 days
Medrol pak 4 mg
Antibiotics
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APPENDIX L
DIFFERENTIAL DIAGNOSIS OF PNEUMONIA PROTOCOL: HF and/or CHF
Heart Failure (HF): It is a complex clinical syndrome that results from any structural or
functional impairment of ventricular filling or ejection of blood.
Congestive Heart Failure (CHF): is reserved for patients with breathlessness and abnormal
sodium and water retention, resulting in edema.
Recognize risk factors by asking about personal history of patient such as hypertension,
atherosclerosis disease, Diabetes Mellitus, metabolic syndrome, valvular disease, myocardial
infarction, myocarditism, heroin, alcohol, cocaine, SE, lupus, RA, and familial
cardiomyopathies.
Evaluate signs/symptoms as to indicators that patient may be experiencing a CHF or HF exacerbation
such as the following: dyspnea, fatigue which may limit exercise tolerance, peripheral edema, neck

vein distention, rales, S3 gallop, acute pulmonary edema, cardiomegaly, increased venous
pressure greated than 16 cm of water, circulation time >25 sec, ankle edema, night cough,
hepatomegaly, pleural efussion, tachycardia, and weight loss greater than 4.5Kg in 5 days in
response to TX.
NP PLAN OF CARE
Order or perform tests to aid in the diagnosis of COPD or not as appropriate to patient’s condition:

2D-Echo and Doppler flow studies, CXR, BNP or NT-Pro-BNP, CBC baseline, BMP baseline
NOTE: CXR may reveal vascular congestion, Kerley B lines, pulmonary edema, increased
interstitial markings, Cardiomegaly, pleural effusion (usually R side but may be bilateral), and
BUN.
NOTE: BNP or NT-Pro-BNP May be elevated
NOTE: Anemia and high proportion of lymphocytes are strong markers of poor survival.
NOTE: Na and K may be low.
NOTE: BUN is normal to elevated.
Using the American College of Cardiology/American Heart Association stages of Heart
Failure identify whether patient is at Stage A, B, C, or D of heart failure.
American College of Cardiology/American Heart Association stages of Heart Failure:
Heart Failure Classifications
Stage Description
A
Presence of conditions (Risk Factors) that are strongly associated with the development
of HF exist.
No identified cardiac structural or functional abnormalities and no symptoms of HF exist.
B
Patient has developed Structural Heart disease that are associated with the development
of HF (Post asymptomatic MI, ventricular dysfunction)
C
Patients who have current or prior symptoms of HF associated with structural heart
disease.
D
Patients with advanced structural heart disease and marked symptoms of heart failure at
rest despite maximal medical therapy and who required heart transplant or left ventricular
assist devices.
Using the Framingham Criteria for the Diagnosis of CHF identify whether patient may have
CHF or not.
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•
•
•
•
•
•
•
•

Framingham Criteria for the Diagnosis of CHF:
2 major criteria or 1 major criteria and 2 minor criteria
Major Criteria
Minor Criteria
Neck vein distention
• Ankle edema
Rales
• Night cough
S3 gallop
• Dyspnea on exertion
Acute pulmonary edema
• Hepatomegaly
Increased venous pressure greater than 16
• Pleural effusion
cm of water
• Tachycardia (HR > 120B/min)
Circulation time >25 sec
• Weight loss greater than 4.5Kg in 5 days in
Cardiomegaly
response to TX.
Paroxysmal nocturnal dyspnea or
orthopnea

Determine whether the patient has heart failure with preserved ejection fraction Stage I, II,
III, or IV by looking at the following table.
HFpEF
Heart Failure with preserved Ejection fraction (previously noted as Diastolic HF)
Stage
Description
I
Mild diastolic impairment: E/A ratio <1.0 due to impaired relaxation and significant
contrinution of atrial contraction to left ventricle(LV)
.
II
Moderate diastolic impairment: E/A is normal , but reversal (ratio < 1.0) occurs with
Valsalva Maneuvers. Due to LV compliance resulting in increased Left atrial (LA)
pressure. E/E ratio is intermediate to elevated.
III
Severe diastolic impairment: Abnormal E/A ratio (>2.0) but changes with Valsalva
Maneuvers. Due to severe decreased in LV compliance causing further increase Left
atrial (LA) pressure. . E/E ratio is high.
IV
(restrictivePhysiology) Abnormal E/A ratio (>2.0) and remains fixed with Valsalva
Maneuvers
Determine whether the patient has heart failure with reduced ejection fraction by looking
at the following table.
HFrEF
Heart Failure with reduced Ejection fraction (previously noted as Systolic HF)
Ejection fraction <40% on 2-D Echo
Treatment Options
• Oxygen therapy
• Diuretics- Loop diuretics are the first choiceOn acute exacerbation of CHF: Furosemide 40 mg IM x1 and may repeat dose in 12 hrs x1
time. Monitor renal function and electrolytes levels daily during therapy.
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•

For maintenance consider Furosemide 40 to 160 mg/dose PO/Oral initially then increase 2040 mg /dose q 12 hrs- (monitor renal function Baseline and electrolytes Baseline and during
treatment)
• ACE Inhibitors• ARB’s- alternative to ACE
• Beta Blockers- First choice Carvedilol low dose 3.125 mg BiD.
• Aldosterone Antagonist- Monitor Potassium levels periodically.
• Hydralazine and Nitrates
Goal of Treatment
• Alleviate symptoms
• Delay Progression
• Reduce Mortality
Possible complications of CHF
• Acute renal Failure- May develop due to diuretics, ACE inhibitors, and poor renal perfusion.
• Pleural effusion- Due to fluid buildup secondary to CHF- Pleural effusion should be treated
with Loop diuretics.
• Anemia- Monitor CBC.
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APPENDIX M
SECONDARY & TERTIARY PREVENTION CHF ASSESSMENT AND PLAN OF CARE
PATIENT NAME
NURSING HOME
ARNP NAME
DATE
PHYSICAL ASSESSMENT
HTN
RA
DM
MI
SE
Lupus
Heroin
Alcohol
Cocaine
Metabolic syndrome
Myocarditis
Artherosclerosis
Valvular disease
Familial Cardiomyopathies
SIGNS/SYMPTOMS
Dyspnea
Rales
Pleural efussion
Tachycardia
S3 gallop
Neck vein distention
Fatigue which may limit exercise tolerance
Peripheral edema
Acute pulmonary edema
Cardiomegaly
Hepatomegaly
Pleural efussion
Circulation time >25 sec
Weight loss greater than 4.5 Kg in 5 days in response to TX
Increased venous pressure greated than 16 cm of water
Night cough
2D-Echo and Doppler flow studies
BMP
BUN

TESTS TO ORDER OR PERFORM
CXR
BNP

ACC/AHA Stage of Heart Failure
Framingham Criteria for Diagnosis of CHF
HFpEF
HFpEF

DIAGNOSIS
A
Y

B
N

NT-Pro-BNP

C

CBC

D

TREATMENT ORDERS
Oxygen Therapy
DIURETICS
Acute exacerbation of CHF
Furosemide 40 mg IM x1 and may repeat dose in 12 hrs x1 time
Monitor renal function and electrolytes levels daily during therapy
Maintenance
Furosemide 40 to 160 mg/dose PO/Oral initially then increase 20-40 mg /dose q 12 hrsMonitor renal function and electrolytes levels daily during therapy
ACE INHIBITORS
ARB'S-ALTERNATIVE TO ACE
BETA BLOKERS
Carvedilol low dose 3.125 mg BiD
ALDOSTERONE ANTAGONIST
Monitor Potassium levels periodically
HYDRALAZINE AND NITRATES
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APPENDIX N: EVALUATION OF RESULTS
Frequency
of data
collection

Frequency
of data
aggregation

Data
analysis

Weekly

Weekly

Descriptive
Statistics

Weekly

Weekly

Descriptive
Statistics

Weekly

Weekly

Descriptive
Statistics

Weekly

Weekly

Descriptive
Statistics

Indicator
Pneumonia
incidents preintervention

Definition
Rate of Patients experiencing pneumonia
symptoms before initiation of secondary
prevention techniques

Data
source
Patient
Chart,
SNF

Pneumonia
incidents postintervention

Rate of Patients experiencing pneumonia
symptoms after initiation of secondary prevention
techniques

Patient
Chart,
SNF

Pneumonia
hospitalization preintervention
Pneumonia
hospitalization
post-intervention

Rate of Patients experiencing hospitalization due
to pneumonia symptoms before initiation of
prevention techniques
Rate of Patients experiencing hospitalization due
to pneumonia symptoms after initiation of
prevention techniques

Patient
Chart,
SNF
Patient
Chart,
SNF

Pneumonia with
CHF DD incidents
pre-intervention

Rate of Patients experiencing pneumonia
symptoms but received diagnosis of CHF as well
before initiation of secondary prevention
techniques

Patient
Chart,
SNF

Weekly

Weekly

Descriptive
Statistics

Pneumonia with
CHF DD incidents
post-intervention

Rate of Patients experiencing pneumonia
symptoms but received diagnosis of CHF as well
before after initiation of secondary prevention
techniques

Patient
Chart,
SNF

Weekly

Weekly

Descriptive
Statistics

Pneumonia with
CHF DD incidents
pre-intervention

Rate of Patients experiencing hospitalization due
to pneumonia symptoms but received diagnosis
of CHF as well before before initiation of
prevention techniques

Patient
Chart,
SNF

Weekly

Weekly

Descriptive
Statistics

Pneumonia
hospitalization
post-intervention

Rate of Patients experiencing hospitalization due
to pneumonia symptoms but received diagnosis
of CHF as well before after initiation of
prevention techniques

Patient
Chart,
SNF

Weekly

Weekly

Descriptive
Statistics

Pneumonia with
COPD DD
incidents preintervention

Rate of Patients experiencing pneumonia
symptoms but received diagnosis of COPD as
well before initiation of secondary prevention
techniques

Patient
Chart,
SNF

Weekly

Weekly

Descriptive
Statistics

Pneumonia with
CHF DD incidents
post-intervention

Rate of Patients experiencing pneumonia
symptoms but received diagnosis of COPD as
well before after initiation of secondary
prevention techniques

Patient
Chart,
SNF

Weekly

Weekly

Descriptive
Statistics

Pneumonia with
CHF DD incidents
pre-intervention

Rate of Patients experiencing hospitalization due
to pneumonia symptoms but received diagnosis
of COPD as well before before initiation of
prevention techniques

Patient
Chart,
SNF

Weekly

Weekly

Descriptive
Statistics

Pneumonia
hospitalization
post-intervention

Rate of Patients experiencing hospitalization due
to pneumonia symptoms but received diagnosis
of COPD as well before after initiation of
prevention techniques

Patient
Chart,
SNF

Weekly

Weekly

Descriptive
Statistics
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APPENDIX O
TRANING OF NURSING HOME STAFF
WEEK OF MAY 1-7, 2017
TRAINING EMPHASIS OF NURSING HOME STAFF
30 minute group meeting to train nursing home staff (RN, LPN, CNA, Charge Nurses)
At each of the five nursing homes
• Trainer(s): Author and Facility NP
• Welcome
• Appendix C Pneumococcal Vaccination and vaccination information sheets (CDC VIS)
• Appendix D and E Influenza Vaccination and CDC VIS
• Appendix F Pneumonia Nursing Home Surveillance
WEEK OF MAY 8-14, 2017
EMPHASIS ON PRIMARY PREVENTION
•
•
•
•

Contact residents and their decision makers (if not the resident) being cared for by project
participating Facility NP regarding improving the health of the residents by providing
personal and community protection against Influenza and Pneumonia.
Emphasize the why get vaccinated portion of the vaccination information sheets when
contacting decision makers, family members or residents.
Set up appointments for patients and/or delegated decision makers to meet with Facility
NP to provide more information and answer questions regarding the vaccines.
Follow guidelines in Appendix C-E as it pertains to vaccination.
PERIOD OF MAY 8- JULY 8, 2017
EMPHASIS ON SECONDARY/TERTIARY PREVENTION

•
•
•

Become a sentinel for the residents especially in detecting pneumonia.
Understand the most likely orders that will be given.
Encourage excellent lines of communication between nursing home staff and facility NP.
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SCHOLARLY QUALITY IMPROVEMENT PROJECT TO REDUCE HOSPITALIZATION
APPENDIX P
TRAINING OF FACILITY NPs BY AUTHOR
2 Hour Group Meeting to Train Facility NPs. Week of March 1-7, 2017
•
•
•

•
•

•
•
•
•
•
•
•
•

Trainer(s): Author
Welcome by the Author
Timeline of Project:
o 5/1-7
Training of NPs regarding project
o 5/1-7
Training of nursing home staff
o 5/8-14
Vaccination Campaign, emphasis Pneumonia Prevention
o 5/8-7/8
Secondary/Tertiary Prevention of Pneumonia
o 7/1-7/15
Tertiary Prevention wrap up
Informed consents to be faxed to and stored in patient’s chart at the facility.
Filled out data collection sheets to be saved as Excel worksheets in secured laptop and
saved as last name, first name, date of service, and appendix alphabet (primary,
secondary, tertiary), (i.e., carrionbertha20170301G.xls). These files should be sent daily
using the secured laptop with VPN and protected email accounts.
Summary of Protocol: Appendix A
Pneumococcal vaccination campaign, Appendices B, C and CDC VIS
Influenza vaccination campaign, Appendices D, E, and CDC VIS
Pneumonia Nursing Home Surveillance (Appendix F and training of nursing home staff)
Secondary Prevention of Pneumonia (Appendices G and H)
Tertiary Prevention of Pneumonia (Appendix I)
Differential diagnosis of COPD, assessment and plan of care (Appendices J and K)
Differential diagnosis of CHF, assessment and plan of care (Appendices L and M)
Weekly One-on-One 1 Hour Meetings from 5/1/2017 to 7/08/2017

•
•
•
•

Review training and communication of nursing home staff, initial and ongoing.
Plan, set goals, and evaluate results and process of protocol implementation.
Address issues, concerns, and questions of importance.
Review cases and possible cases.
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